Please click on the banner image above to watch the dialogue.
“We’re in the age of precision medicine. I think we need to move into precision health promotion, precision medical education to provide very targeted, very personalized medical advice for each individual, and to be able to better measure the outcomes at the individual level.” – Benjamin Seet
Episode IV of the “Dialogues on Healthy Aging” features Benjamin Seet, Deputy Group CEO (Education and Research), National Healthcare Group in Singapore with moderation by Hui Cai, VP and Head of Content, WuXi AppTec.
Key discussions around:
– As one of the fastest aging societies in the world, what unique challenges does Singapore’s healthcare system face?
– How is the Singapore healthcare system adapting to the new reality?
– How do you see the healthcare system in Singapore changing over the next ten years in response to the growing need of aging patients?
– As a well-recognized world leader in education and research, how research in Singapore is making an impact on healthcare?
Ben Seet is the Deputy Group CEO (Education & Research) for the National Healthcare Group, and concurrently, Assistant CEO of Tan Tock Seng Hospital (Corporate Services). He is an Adjunct Professor with the Lee Kong Chian School of Medicine.
Ben was formerly Executive Director of the Biomedical Research Council at A*STAR, where he oversaw research and innovation spanning the pharmaceutical, biotech, health tech, food and consumer industries. Prior to joining A*STAR, he served a 22-year military career, where he held the appointment of Chief of the SAF Medical Corps. He further served as Chief Medical Officer of the UN Department of Peacekeeping Operations in New York.
Ben serves on various boards and advisory committees. He currently sees himself as an evangelist for COVID-19 vaccination.
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President and Head of Content Division.
Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 50 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS), a member of BayHelix, and a member of the UCSD Alumni Board. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.